C10: Lipid modifying agents

Pharmacometric modeling notes for ATC C10, lipid modifying agents.
Modified

September 21, 2026

Part of C: Cardiovascular system.

Mechanistic extrapolation. PBPK dominates here, predicting OATP1B1 transporter-mediated statin interactions and SLCO1B1 genotype effects on exposure; cardiorenal QSP models extrapolate blood-pressure and renal responses for antihypertensives [1,2].

References

[1]
Yoshikado T, Yoshida K, Kotani N, Nakada T, Asaumi R, Toshimoto K, et al. Quantitative analyses of hepatic OATP-mediated interactions between statins and inhibitors using PBPK modeling with a parameter optimization method. Clinical Pharmacology & Therapeutics 2016;100:513–23. https://doi.org/10.1002/cpt.391.
[2]
Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, et al. A mechanistic framework for in vitro–in vivo extrapolation of liver membrane transporters: Prediction of drug–drug interaction between rosuvastatin and cyclosporine. Clinical Pharmacokinetics 2014;53:73–87. https://doi.org/10.1007/s40262-013-0097-y.